

Customer No.: 20462  
Attorney Docket No. PU60398  
Confirmation No.: 3933

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Belmonte, et al. 23 January 2008  
Serial No.: 10/565,046 Group Art Unit No.: 1625  
Filed: 17 January 2006 Examiner: N. Rahmani  
For: Muscarinic Acetylcholine Receptor Antagonists

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

Applicants respectfully request that the USPTO disregard the Information Disclosure Statement filed 22 May 2007. The Zirkle US 2,800,482 reference has been cited on the accompanying IDS. The Peters et al. reference was cited in error. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the file wrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Should the Examiner have any questions or comments please contact the undersigned at the number indicated below.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5017  
Facsimile (610) 270-5090